[7, 11, 13-15] Given the large drop-out rates, a majority of the studies notably failed to discuss whether the baseline characteristics of participants who withdrew were statistically significantly different to the remaining http://www.selleckchem.com/
participants[7, 11, 13, 15], and two of the studies did not use or failed to mention whether analysis was by intention-to-treat.[7, 15] In addition, only one of the six studies followed up participants monitoring the long-term effectiveness and the tolerability profile of the studied antidepressant, whereas another did not monitor changes in depression level. The outcomes measured differed considerably between the six studies and varyingly included chest pain frequency, intensity and/or severity. To achieve consistency for reporting purposes, the percentage reduction of any combination of these outcomes was calculated (Figure?2). The percentage reduction in chest pain severity with sertraline (P?=?0.02), frequency with imipramine (P?=?0.03) and intensity (severity?��?frequency) with venlafaxine (P?<?0.001) were all statistically significant. Interestingly, although Cannon et?al. also measured and demonstrated a significantly <a href="http://www.selleckchem.com/products/GDC-0449.html
">learn more lower intensity of chest pain during the administration of imipramine, when compared with the placebo group, this was not significant. Similarly, the percentage reduction in pain score between paroxetine and placebo in the Doraiswamy et?al. study and the percentage reduction in pain index (derived from chest pain duration and intensity) in the Spinhoven et?al. study were both statistically insignificant. The Clouse et?al. study was not included in Figure?2 as sufficient data could not be extrapolated from the graphs provided. However, the study showed no significant difference Casein kinase 2
between the placebo and trazodone group in chest pain frequency and intensity. Clinical improvement scores were also collated in five of the six studies. The studies examined different clinical improvement areas such as chest pain, functional impairment, anxiety scale, body pain, general health, emotions and global improvement. With the exception of the paroxetine study by Doraiswamy et?al., clinical improvement scores were obtained from participants, allowing them to provide feedback at the end of the trial on their overall progress during the study period. Conversely, in the Doraiswamy et?al. study, physicians rated the clinical global impression of improvement for the patients and, it should be noted that this was the only statistically significant finding from the study �C Clinical Global Severity ratings, and Short Form 36 Health Survey (SF-36) were also measured, but were not statistically significant.